William Nseir1,2,3, Zuhair Abu-Rahmeh4, Alex Tsipis5, Julnar Mograbi1,2, Mahmud Mahamid1,2,3. 1. Department of Internal Medicine, Holy Family Hospital, Nazareth, Israel. 2. Division of Internal Medicine, Nazareth Hospital EMMS, Nazareth, Israel. 3. Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel. 4. Department of Radiology, Breast Center, Holy Family Hospital, Nazareth, Israel. 5. Department of Radiology, Ziv Medical Center, Safed, Israel.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which refers to the presence of hepatic steatosis. Breast cancer is now the most common cancer in women and is the leading cause of death from cancer among women. OBJECTIVES: To assess the relationship between NAFLD and newly diagnosed cases of breast cancer. METHODS: The results of mammography screening examinations in women referred to the Breast Center, Holy Family Hospital, Nazareth during a 4 year period were collected. We identified cases of women who were newly diagnosed with breast cancer and who underwent abdominal computed tomography (CT) within 1 month of the diagnosis. The control group comprised 73 women with normal mammography and breast ultrasonography who underwent abdominal CT within 3 months from the date of the breast cancer screening during the same study period. The control cases were matched by age and body mass index (BMI). We compared the cases with the controls in terms of the presence of diffuse hepatic fatty liver and other known risk factors for breast cancer. RESULTS: Of the 133 women who were screened, 73 with new diagnosis of breast cancer were eligible for the study. NAFLD was found in 33 of the women with breast cancer and in 12 in the control group (45.2% vs.16.4%, respectively, P = 0.002). Multivariate analysis showed NAFLD (odds ratio 2.82, 95% confidence interval 1.2-5.5, P = 0.016) to be associated with breast cancer. CONCLUSIONS: NAFLD is associated with breast cancer.
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which refers to the presence of hepatic steatosis. Breast cancer is now the most common cancer in women and is the leading cause of death from cancer among women. OBJECTIVES: To assess the relationship between NAFLD and newly diagnosed cases of breast cancer. METHODS: The results of mammography screening examinations in women referred to the Breast Center, Holy Family Hospital, Nazareth during a 4 year period were collected. We identified cases of women who were newly diagnosed with breast cancer and who underwent abdominal computed tomography (CT) within 1 month of the diagnosis. The control group comprised 73 women with normal mammography and breast ultrasonography who underwent abdominal CT within 3 months from the date of the breast cancer screening during the same study period. The control cases were matched by age and body mass index (BMI). We compared the cases with the controls in terms of the presence of diffuse hepatic fatty liver and other known risk factors for breast cancer. RESULTS: Of the 133 women who were screened, 73 with new diagnosis of breast cancer were eligible for the study. NAFLD was found in 33 of the women with breast cancer and in 12 in the control group (45.2% vs.16.4%, respectively, P = 0.002). Multivariate analysis showed NAFLD (odds ratio 2.82, 95% confidence interval 1.2-5.5, P = 0.016) to be associated with breast cancer. CONCLUSIONS: NAFLD is associated with breast cancer.
Authors: Mark G Swain; Alnoor Ramji; Keyur Patel; Giada Sebastiani; Abdel Aziz Shaheen; Edward Tam; Paul Marotta; Magdy Elkhashab; Harpreet S Bajaj; Chris Estes; Homie Razavi Journal: CMAJ Open Date: 2020-06-09
Authors: Young-Sun Lee; Ha Seok Lee; Sung Won Chang; Chan Uk Lee; Jung Sun Kim; Young Kul Jung; Ji Hoon Kim; Yeon Seok Seo; Hyung Joon Yim; Chang Hee Lee; Sang Uk Woo; Jae Hong Seo; Jong Eun Yeon; Soon Ho Um; Kwan Soo Byun Journal: Medicine (Baltimore) Date: 2019-09 Impact factor: 1.817